Revolutionizing the provision of patient care, improving outcomes and reducing overall cost through new medical technologies is serious business. It takes vision, technical prowess and efficient use of scarce resources in a rigorous regulatory landscape.
Last month, The New York Times included the work GCMI and the American Cancer Society are doing with Dr. Darren Robyler to help bring BOTLab’s NIR technology to bear on real-time verification of chemotherapy effectiveness for breast cancer patients.
From “Looking to Technology to Avoid Doctors’ Offices and Emergency Rooms:”
“Technology every day is playing a more important role in preventing and even diagnosing illness,” said Gary Shapiro, chief executive of the Consumer Technology Association. “We are just beginning this journey of revolutionizing health care and reducing trips to the doctor.”
Among the new inventions are many that use artificial intelligence, sensors or so-called internet of things (IoT) connectivity to do a host of groundbreaking tasks, from detecting Alzheimer’s from the sound of your voice to telling breast cancer patients, in real-time, if their chemotherapy treatment is working.
Read the article in its entirety including reporter Janet Morrissey’s description of BOTLabs’ solution and implications for women battling breast cancer and the clinicians who care for them.
BOTLab was the first American Cancer Society supported technology to enter GCMI’s A1 accelerator as we reported last year.
Thank you to all who contributed to raising the awareness for who we are and what we do in the interest of accelerating medtech innovation in order to improve the provision of care and reduce overall healthcare spending.
If you’d like to know more about our accelerator, design and development capabilities, facilities including T3 Labs or your own prospective FDA pathway, contact us today.